Clover Biopharmaceuticals, Ltd. (HKG:2197)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.760
-0.100 (-3.50%)
May 7, 2026, 4:08 PM HKT

Revenue by Segment

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Research, Development, Manufacturing & Commercialization of Innovative Vaccines
3.51M38.42M39.26M--
Research, Development, Manufacturing & Commercialization of Innovative Vaccines Growth
-90.88%-2.13%---
Total
3.51M38.42M39.26M--
Total Growth
-90.88%-2.13%---

Revenue by Geography

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Mainland China
3.51M35.18M39.26M--
Mainland China Growth
-90.04%-10.39%---
Korea
-3.24M---
Total
3.51M38.42M39.26M--
Total Growth
-90.88%-2.13%---
Source: S&P Global Market Intelligence.